FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1836436171> ?p ?o ?g. }

• W1836436171 endingPage "94" @default.
• W1836436171 startingPage "1488" @default.
• W1836436171 abstract "To evaluate the clinical and serological heterogeneity in patients with anticentromere antibodies (ACA).One hundred twenty patients with ACA were analyzed retrospectively. ACA were detected initially on the basis of indirect immunofluorescence on HEp-2 cells, and then antibodies to CENP-B were measured by ELISA. Antibodies to other nuclear antigens were also detected by double immunodiffusion and/or ELISA.Eighty-four patients (70.0%) had systemic sclerosis (SSc; scleroderma) and 36 patients (30.0%) had other rheumatic diseases or miscellaneous disorders. Among patients with SSc, 35 patients (41.7%) had SSc in overlap mostly with Sjögren's syndrome (SS), in part with rheumatoid arthritis and/or primary biliary cirrhosis (PBC). Five of 36 patients (13.9%) without SSc also had overlap syndrome of more than 2 rheumatic diseases or PBC. All CREST features (calcinosis, Raynaud's, esophageal dysmotility, sclerodactyly, telangiectasias) were found significantly more in SSc than in other diseases. A combination of RST was the most frequently seen, followed by CREST and CRST in the SSc group. In contrast, 22 of 36 patients (61.1%) without SSc had no CREST features, and the rest had only Raynaud's phenomenon and/or telangiectasia. Twenty-five of 75 patients (33.3%) with SSc and 6 of 25 patients (24.0%) with other diseases had a slight elevation of creatine phosphokinase concentration with no apparent myositis signs and/or skin lesions, suggesting a new additional sign of patients with ACA. Seventy-two patients (60.0%) had ACA alone and 48 patients (40%) had ACA mixed with other disease marker antinuclear antibodies (ANA). ACA alone occurred more frequently in patients with SSc and in the non-overlap group, whereas patients with ACA mixed with other ANA were more frequently found in the other disease and the overlap syndrome groups. Anti-CENP-B ELISA levels of the SSc group were significantly higher than those of other disease groups in all patients, in patients with ACA alone, and in patients having ACA together with other ANA. The most frequently concurrent ANA were anti-SSA/Ro antibodies; and the other ANA, including anti-SSB/La, RNP, topoisomerase-I, Jo-1, Ku, and dsDNA antibodies, were also positive alone or combined with more than 2 ANA in patients with ACA. Five patients with CREST syndrome having ACA and anti-RNP antibodies had clinical manifestations compatible with mixed connective tissue disease. SS was found in 37.0% of patients who had higher anti-CENP-B ELISA levels and higher coincidence of anti-SSA/Ro antibodies than the patients without SS.ACA were positive mostly in patients with SSc with CREST features and partly in other rheumatic disorders. The high levels of ACA may be necessary for the development of CREST features, and frequent concurrence of other disease marker ANA may contribute to the development of heterogeneous clinical characteristics, including overlap syndrome, in patients with ACA." @default.
• W1836436171 created "2016-06-24" @default.
• W1836436171 creator A5018101881 @default.
• W1836436171 creator A5027785553 @default.
• W1836436171 creator A5048648923 @default.
• W1836436171 creator A5089290959 @default.
• W1836436171 date "2005-08-01" @default.
• W1836436171 modified "2023-10-03" @default.
• W1836436171 title "Clinical and serological heterogeneity in patients with anticentromere antibodies." @default.
• W1836436171 cites W1542014548 @default.
• W1836436171 cites W1977209683 @default.
• W1836436171 cites W1989678120 @default.
• W1836436171 cites W2002027999 @default.
• W1836436171 cites W2023421586 @default.
• W1836436171 cites W2047332694 @default.
• W1836436171 cites W2052542265 @default.
• W1836436171 cites W2073898388 @default.
• W1836436171 cites W2078424179 @default.
• W1836436171 cites W2086269921 @default.
• W1836436171 cites W2102687543 @default.
• W1836436171 cites W2129962217 @default.
• W1836436171 cites W2143611289 @default.
• W1836436171 cites W2148696792 @default.
• W1836436171 cites W2149777420 @default.
• W1836436171 cites W2285534666 @default.
• W1836436171 cites W2299513640 @default.
• W1836436171 cites W2406662068 @default.
• W1836436171 cites W56619614 @default.
• W1836436171 cites W97060029 @default.
• W1836436171 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16078324" @default.
• W1836436171 hasPublicationYear "2005" @default.
• W1836436171 type Work @default.
• W1836436171 sameAs 1836436171 @default.
• W1836436171 citedByCount "32" @default.
• W1836436171 countsByYear W18364361712012 @default.
• W1836436171 countsByYear W18364361712013 @default.
• W1836436171 countsByYear W18364361712014 @default.
• W1836436171 countsByYear W18364361712015 @default.
• W1836436171 countsByYear W18364361712016 @default.
• W1836436171 countsByYear W18364361712017 @default.
• W1836436171 countsByYear W18364361712018 @default.
• W1836436171 countsByYear W18364361712020 @default.
• W1836436171 countsByYear W18364361712021 @default.
• W1836436171 countsByYear W18364361712022 @default.
• W1836436171 countsByYear W18364361712023 @default.
• W1836436171 crossrefType "journal-article" @default.
• W1836436171 hasAuthorship W1836436171A5018101881 @default.
• W1836436171 hasAuthorship W1836436171A5027785553 @default.
• W1836436171 hasAuthorship W1836436171A5048648923 @default.
• W1836436171 hasAuthorship W1836436171A5089290959 @default.
• W1836436171 hasConcept C126322002 @default.
• W1836436171 hasConcept C142724271 @default.
• W1836436171 hasConcept C149443304 @default.
• W1836436171 hasConcept C159654299 @default.
• W1836436171 hasConcept C163764329 @default.
• W1836436171 hasConcept C180032290 @default.
• W1836436171 hasConcept C198451711 @default.
• W1836436171 hasConcept C203014093 @default.
• W1836436171 hasConcept C2775917601 @default.
• W1836436171 hasConcept C2775941666 @default.
• W1836436171 hasConcept C2775981168 @default.
• W1836436171 hasConcept C2776670291 @default.
• W1836436171 hasConcept C2776780178 @default.
• W1836436171 hasConcept C2777575956 @default.
• W1836436171 hasConcept C2779075594 @default.
• W1836436171 hasConcept C2779134260 @default.
• W1836436171 hasConcept C2779967694 @default.
• W1836436171 hasConcept C2780309369 @default.
• W1836436171 hasConcept C2781232998 @default.
• W1836436171 hasConcept C2910997768 @default.
• W1836436171 hasConcept C45189115 @default.
• W1836436171 hasConcept C71924100 @default.
• W1836436171 hasConcept C90924648 @default.
• W1836436171 hasConceptScore W1836436171C126322002 @default.
• W1836436171 hasConceptScore W1836436171C142724271 @default.
• W1836436171 hasConceptScore W1836436171C149443304 @default.
• W1836436171 hasConceptScore W1836436171C159654299 @default.
• W1836436171 hasConceptScore W1836436171C163764329 @default.
• W1836436171 hasConceptScore W1836436171C180032290 @default.
• W1836436171 hasConceptScore W1836436171C198451711 @default.
• W1836436171 hasConceptScore W1836436171C203014093 @default.
• W1836436171 hasConceptScore W1836436171C2775917601 @default.
• W1836436171 hasConceptScore W1836436171C2775941666 @default.
• W1836436171 hasConceptScore W1836436171C2775981168 @default.
• W1836436171 hasConceptScore W1836436171C2776670291 @default.
• W1836436171 hasConceptScore W1836436171C2776780178 @default.
• W1836436171 hasConceptScore W1836436171C2777575956 @default.
• W1836436171 hasConceptScore W1836436171C2779075594 @default.
• W1836436171 hasConceptScore W1836436171C2779134260 @default.
• W1836436171 hasConceptScore W1836436171C2779967694 @default.
• W1836436171 hasConceptScore W1836436171C2780309369 @default.
• W1836436171 hasConceptScore W1836436171C2781232998 @default.
• W1836436171 hasConceptScore W1836436171C2910997768 @default.
• W1836436171 hasConceptScore W1836436171C45189115 @default.
• W1836436171 hasConceptScore W1836436171C71924100 @default.
• W1836436171 hasConceptScore W1836436171C90924648 @default.
• W1836436171 hasIssue "8" @default.
• W1836436171 hasLocation W18364361711 @default.

• next